Lifecore Biomedical (LFCR) Competitors $5.61 -0.12 (-2.09%) Closing price 02/21/2025 04:00 PM EasternExtended Trading$5.73 +0.12 (+2.12%) As of 02/21/2025 07:09 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends LFCR vs. AVBP, COGT, OCS, BCYC, DNA, IMNM, AVDL, CVAC, CDMO, and NUVBShould you be buying Lifecore Biomedical stock or one of its competitors? The main competitors of Lifecore Biomedical include ArriVent BioPharma (AVBP), Cogent Biosciences (COGT), Oculis (OCS), Bicycle Therapeutics (BCYC), Ginkgo Bioworks (DNA), Immunome (IMNM), Avadel Pharmaceuticals (AVDL), CureVac (CVAC), Avid Bioservices (CDMO), and Nuvation Bio (NUVB). These companies are all part of the "pharmaceutical products" industry. Lifecore Biomedical vs. ArriVent BioPharma Cogent Biosciences Oculis Bicycle Therapeutics Ginkgo Bioworks Immunome Avadel Pharmaceuticals CureVac Avid Bioservices Nuvation Bio ArriVent BioPharma (NASDAQ:AVBP) and Lifecore Biomedical (NASDAQ:LFCR) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, institutional ownership, earnings, risk, dividends, valuation, analyst recommendations, community ranking and media sentiment. Which has better valuation & earnings, AVBP or LFCR? Lifecore Biomedical has higher revenue and earnings than ArriVent BioPharma. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioArriVent BioPharmaN/AN/A-$69.33MN/AN/ALifecore Biomedical$128.26M1.62$12.01M-$0.56-10.02 Do analysts recommend AVBP or LFCR? ArriVent BioPharma currently has a consensus target price of $38.00, suggesting a potential upside of 40.38%. Lifecore Biomedical has a consensus target price of $8.00, suggesting a potential upside of 42.60%. Given Lifecore Biomedical's higher probable upside, analysts plainly believe Lifecore Biomedical is more favorable than ArriVent BioPharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ArriVent BioPharma 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00Lifecore Biomedical 0 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.33 Do institutionals & insiders have more ownership in AVBP or LFCR? 9.5% of ArriVent BioPharma shares are owned by institutional investors. Comparatively, 83.4% of Lifecore Biomedical shares are owned by institutional investors. 28.2% of Lifecore Biomedical shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. Does the media prefer AVBP or LFCR? In the previous week, ArriVent BioPharma had 1 more articles in the media than Lifecore Biomedical. MarketBeat recorded 1 mentions for ArriVent BioPharma and 0 mentions for Lifecore Biomedical. ArriVent BioPharma's average media sentiment score of 1.95 beat Lifecore Biomedical's score of 0.00 indicating that ArriVent BioPharma is being referred to more favorably in the media. Company Overall Sentiment ArriVent BioPharma Very Positive Lifecore Biomedical Neutral Does the MarketBeat Community favor AVBP or LFCR? ArriVent BioPharma received 14 more outperform votes than Lifecore Biomedical when rated by MarketBeat users. Likewise, 100.00% of users gave ArriVent BioPharma an outperform vote while only 25.00% of users gave Lifecore Biomedical an outperform vote. CompanyUnderperformOutperformArriVent BioPharmaOutperform Votes17100.00% Underperform VotesNo VotesLifecore BiomedicalOutperform Votes325.00% Underperform Votes975.00% Is AVBP or LFCR more profitable? ArriVent BioPharma has a net margin of 0.00% compared to Lifecore Biomedical's net margin of -12.52%. ArriVent BioPharma's return on equity of -43.89% beat Lifecore Biomedical's return on equity.Company Net Margins Return on Equity Return on Assets ArriVent BioPharmaN/A -43.89% -29.67% Lifecore Biomedical -12.52%-315.23%-12.74% SummaryArriVent BioPharma beats Lifecore Biomedical on 8 of the 14 factors compared between the two stocks. Get Lifecore Biomedical News Delivered to You Automatically Sign up to receive the latest news and ratings for LFCR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart LFCR vs. The Competition Export to ExcelMetricLifecore BiomedicalPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$212.15M$7.06B$5.84B$9.14BDividend YieldN/A2.76%4.76%3.85%P/E RatioN/A2.9318.2614.95Price / Sales1.62281.18434.4770.76Price / CashN/A65.9238.4235.17Price / Book15.166.717.644.65Net Income$12.01M$138.11M$3.18B$245.69M7 Day Performance-7.88%-2.54%-1.95%-2.68%1 Month Performance-12.75%-2.00%-0.23%-2.16%1 Year Performance-28.17%-5.04%16.69%12.90% Lifecore Biomedical Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)LFCRLifecore Biomedical2.6655 of 5 stars$5.61-2.1%$8.00+42.6%-30.1%$212.15M$128.26M0.00690AVBPArriVent BioPharma1.2029 of 5 stars$26.60-0.9%$37.40+40.6%+36.2%$896.34MN/A0.0040COGTCogent Biosciences1.5442 of 5 stars$8.03-1.8%$14.33+78.5%-6.5%$886.99MN/A-3.2480OCSOculis2.4826 of 5 stars$21.590.0%$28.80+33.4%+70.9%$874.40M$980,000.00-11.192BCYCBicycle Therapeutics2.84 of 5 stars$12.55+0.5%$33.25+164.9%-49.7%$866.58M$26.98M-3.81240News CoverageDNAGinkgo Bioworks0.8594 of 5 stars$14.73+8.7%$4.58-68.9%N/A$846.38M$217.11M-1.131,218Upcoming EarningsNews CoverageGap UpIMNMImmunome2.9788 of 5 stars$10.40-0.3%$28.60+175.0%-56.7%$829.71M$14.02M-1.2840Positive NewsAVDLAvadel Pharmaceuticals3.8538 of 5 stars$8.61-4.2%$19.88+130.8%-33.7%$829.66M$27.96M-10.9070Positive NewsCVACCureVac4.0973 of 5 stars$3.65flat$10.00+174.0%-3.5%$817.16M$58.18M6.641,172News CoverageCDMOAvid Bioservices2.2546 of 5 stars$12.50+0.1%$12.25-2.0%+68.9%$799.18M$139.91M-5.23320High Trading VolumeNUVBNuvation Bio2.0493 of 5 stars$2.28-0.7%$8.20+260.4%+23.9%$765.70MN/A-1.0560 Related Companies and Tools Related Companies ArriVent BioPharma Competitors Cogent Biosciences Competitors Oculis Competitors Bicycle Therapeutics Competitors Ginkgo Bioworks Competitors Immunome Competitors Avadel Pharmaceuticals Competitors CureVac Competitors Avid Bioservices Competitors Nuvation Bio Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:LFCR) was last updated on 2/22/2025 by MarketBeat.com Staff From Our PartnersSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...Timothy Sykes | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredWhy Buffett and 100 members of Congress are Piling into this One InvestmentThis isn't just another investment. It might be the last retirement stock you'll ever need. But this win...Behind the Markets | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | SponsoredThis Crypto Is Set to Explode in FebruaryIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredMarket down? Do this now.During Trump's first term, his tariffs sent gold prices soaring. Investors who acted early made a fortune. Now...Colonial Metals | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lifecore Biomedical, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Lifecore Biomedical With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
